| Literature DB >> 35327010 |
Alessandro Buda1, Giampaolo Di Martino2, Martina Borghese3, Stefano Restaino4, Alessandra Surace1, Andrea Puppo3, Sara Paracchini1, Debora Ferrari2, Stefania Perotto1, Antonia Novelli3, Elena De Ponti5, Chiara Borghi1, Francesco Fanfani6,7, Robert Fruscio2.
Abstract
The aim of our study was to evaluate the benefits of a low-pressure insufflation system (AirSeal) vs. a standard insufflation system in terms of anesthesiologists' parameters and postoperative pain in patients undergoing laparoscopic surgery for early-stage endometrial cancer. This retrospective study involved five tertiary centers and included 152 patients with apparent early-stage disease who underwent laparoscopic surgical staging with either the low-pressure AirSeal system (8-10 mmHg, n = 84) or standard laparoscopic insufflation (10-12 mmHg, n = 68). All the intraoperative anesthesia variables evaluated (systolic blood pressure, end-tidal CO2, peak airway pressure) were significantly lower in the AirSeal group. We recorded a statistically significant difference between the two groups in the median NRS scores for global pain recorded at 4, 8, and 24 h, and for overall shoulder pain after surgery. Significantly more women in the AirSeal group were also discharged on day one compared to the standard group. All such results were confirmed when analyzing the subgroup of women with a BMI >30 kg/m2. In conclusion, according to our preliminary study, low-pressure laparoscopy represents a valid alternative to standard laparoscopy and could facilitate the development of outpatient surgery.Entities:
Keywords: endometrial cancer; laparoscopy; low-pressure insufflation; postoperative pain
Year: 2022 PMID: 35327010 PMCID: PMC8953067 DOI: 10.3390/healthcare10030531
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Figure 1NRS pain control score of the two groups at 4, 8 and 24 h after surgery.
General characteristics of the study groups.
| Variables | AirSeal (N = 84) | Standard (N = 68) | |
|---|---|---|---|
| Age | |||
| median (range) | 63 (52–73) | 65 (54–75) | |
| 0.275 | |||
| BMI, kg/m2, median (range) | 30.0 (23.7–36.4) | 27.9 (22.6–33.2) | 0.142 |
| FIGO stage, n (%) | 0.980 | ||
| IA | 54 (64.3) | 44 (65.7) | |
| IB | 14 (16.7) | 12 (17.9) | |
| II | 4 (4.8) | 3 (4.5) | |
| III | 12 (14.3) | 8 (11.9) | |
| Atypical Hyperplasia | - | 1 | |
| Grading, n (%) | 0.006 | ||
| G1 | 48 (57.1) | 20 (31.3) | |
| G2 | 24 (28.6) | 27 (42.2) | |
| G3 | 12 (14.3) | 17 (26.6) | |
| NA | 0 | 4 | |
| Histotype, n (%) | 0.013 | ||
| Complex hyperplasia | 0 | 1 (1.5) | |
| Endometrioid | 80 (95.2) | 58 (85.3) | |
| Serous | - | 6 (8.8) | |
| MMT & others | 4 (4.8) | 3 (4.4) | |
| LVSI, n (%) | 0.121 | ||
| Present | 23 (27.4) | 12 (17.7) | |
| Absent | 59 (72.6) | 56 (82.3) | |
| NA | 2 | 0 | |
| Previous surgery, n (%) | 28 (33.3) | 29 (42.7) | 0.174 |
| Smoke habit, n (%) | 29 (34.5) | 23 (33.8) | 0.507 |
| Pulmonary disease, n (%) | 11 (13.1) | 11 (16.2) | 0.393 |
| ASA score, n (%) | 0.433 | ||
| 1 | 12 (14.3) | 7 (10.3) | |
| 2 | 43 (51.2) | 42 (61.8) | |
| 3 | 29 (34.5) | 19 (27.9) |
Surgical and anaesthesiology parameters.
| Variable | AirSeal (N = 84) | Standard (N = 68) | |
|---|---|---|---|
| Estimated blood loss, mL | 0.880 | ||
| median (range) | 122.0 (77.6–166.4) | 121.0 (79.6–162.4) | |
| SLN detection, n (%) | 0.176 | ||
| Bilateral | 70 (83.3) | 52 (76.5) | |
| Monolateral | 9 (10.7) | 13 (19.1) | |
| Failed mapping | 5 (6) | 3 (4.4) | |
| Lymph nodes removed | 4 (0–9) | 7 (0–17) | 0.101 |
| median (range) | |||
| CO2 IAP, mmHg | |||
| median (range) | 8.5 (7.5–9.5) | 11.3 (10.2–12.4) | <0.0001 |
| Global pain at 4 h, | |||
| median (range) | 1.4 (0.4–2.4) | 1.7 (0.9–2.5) | 0.023 |
| Global pain at 8 h, | |||
| median (range) | 0.8 (0–1.6) | 1.4 (0.7–2.1) | <0.0001 |
| Global pain at 24 h, | 0.2 (0–0.8) | ||
| median (range) | 1.1 (0.2–2.0) | <0.0001 | |
| Shoulder pain, n (%) | |||
| Yes | 6 (7.1) | 20 (29.4) | |
| No | 78 (92.9) | 48 (70.6) | <0.0001 |
| Morphine consumption, n (%) | |||
| Yes | 4 (4.8) | 19 (27.9) | |
| No | 80 (95.2) | 49 (72.1) | <0.0001 |
| ETCO2, mmHg, | |||
| median (range) | 33.7 (31.4–36.0) | 35.8 (32.3–39.3) | <0.0001 |
| Peak airway pressure, cm H2O, median (range) | |||
| 21.8 (16.3–27.3) | 24.8 (21.5–28.1) | <0.0001 | |
| Max systolic arterial pressure, mmHg, median (range) | |||
| 111.7 (98.2–125.2) | 133.5 (119.7–147.3) | <0.0001 | |
| Total CO2 used, liters, | |||
| median (range) | 34.1 (29.9–38.3) | 47.9 (41.7–54.1) | <0.0001 |
| Duration of surgery, minutes, median (range) | . | ||
| 113 (91.8–134.2) | 119 (84.4–153.6) | 0.445 | |
| Length of stay, days, | 2.0 (1.4–2.6) | 2.2 (1.4–3.0) | 0.224 |
| median (range) | |||
| Major complications, n (%) | 0 | 2 (2.9) | - |
Analysis in the subgroup of obese women with BMI greater than 30 kg/m2 (N = 77).
| Variables | AirSeal | Standard | |
|---|---|---|---|
| (n° = 32) | (n° = 35) | ||
| Age | |||
| median (range) | 62 (58–69.3) | 65 (57–77) | 0.343 |
| Previous surgery | |||
| yes | 11 (34.4%) | 18 (51.4%) | 0.123 |
| Smoke habit | |||
| yes | 12 (37.5%) | 10 (28.6%) | 0.603 |
| Pulmonary disease | |||
| yes | 6 (18.8%) | 8 (22.9%) | 0.457 |
| ASA, n (%) | |||
| 1 | 5 (15.6%) | 1 (2.9%) | |
| 2 | 15 (46.9%) | 23 (65.7%) | 0.137 |
| 3 | 12 (37.5%) | 11 (31.4%) | |
| Et-CO2, | |||
| median (range) | 32 (31–33) | 34 (32.4–37) | 0.0004 |
| Peak airway pressure, median (range) | |||
| 19 (17–22.4) | 25 (20–25) | 0.0030 | |
| Max systolic pressure | |||
| median (range) | 105 (95–116.3) | 130 (120–137.2) | <0.0001 |
| Total CO2 used, liters | |||
| Median (range) | 30 (30–35) | 45 (40–50) | <0.0001 |
| Surgical time, minutes, | |||
| median (range) | 100 (90.120) | 101.9 (80–130) | 0.283 |
| Blood loss, mL, | |||
| median (range) | 100 (99.6–100) | 100 (100–120) | 0.497 |
| NRS pain at 4 h, median (range) | |||
| 1 (0–1) | 1 (1–2) | 0.062 | |
| NRS pain at 8 h | |||
| median (range) | 0 (0–1) | 1 (0–1) | 0.0034 |
| NRS pain at 24 h | |||
| median (range) | 0 (0–0) | 1 (0–1) | 0.0005 |
| Shoulder pain, n (%) | |||
| yes | 2 (6.3) | 10 (28.6) | 0.018 |
| Morphine consumption, n (%) | |||
| yes | |||
| 2 (6.3) | 14 (40.0) | 0.001 | |
| Length of stay, days | |||
| 1–2 | 28 (87.5) | 24 (68.6) | |
| 3 | 4 (12.5) | 11 (31.4) | 0.058 |